Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease

Movement Disorders

Volumn 31, Issue 8, 2016, Pages 1192-1202

  Marras, Connie ^a   Alcalay, Roy N ^b   Caspell Garcia, Chelsea ^c   Coffey, Christopher ^c   Chan, Piu ^d   Duda, John E ^e   Facheris, Maurizio F ^f   Fernández Santiago, Rubén ^g   Ruíz Martínez, Javier ^h   Mestre, Tiago ^a,i   Saunders Pullman, Rachel ^j   Pont Sunyer, Claustre ^g   Tolosa, Eduardo ^g   Waro, Bjorg ^k  

^a UNIVERSITY OF TORONTO   (Canada)

^b Department of Medicine   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^g UNIVERSITY OF BARCELONA   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

more..

Author keywords

LRRK2; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEVODOPA; LRRK2 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GAIT DISORDER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GERIATRIC DEPRESSION SCALE; HETEROZYGOTE; HUMAN; IDIOPATHIC DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MOTOR DYSFUNCTION; ODOR RECOGNITION TEST; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; SEX; UNIFIED PARKINSON DISEASE RATING SCALE; UNIVERSITY OF PENNSYLVANIA SMELL IDENTIFICATION TEST; CLASSIFICATION; CLINICAL TRIAL; COHORT ANALYSIS; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84963971784     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26614     Document Type: Article

References (36)

1. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
2. Aasly JO, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005;57:762-765.
3. Gosal D, Ross OA, Wiley J, et al. Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. Parkinsonism Relat Disord 2005;11:349-352.
4. Ruiz-Martinez J, Gorostidi A, Goyenechea E, et al. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. Mov Disord 2011;26:2026-2031.
5. Tijero B, Gomez Esteban JC, Somme J, et al. Autonomic dysfunction in parkinsonian LRRK2 mutation carriers. Parkinsonism Relat Disord 2013;19:906-909.
6. Valldeoriola F, Gaig C, Muxi A, et al. 123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations. J Neurol 2011;258:1126-1132.
7. Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005;128:2786-2796.
8. Alcalay RN, Mejia Santana H, Mirelman A, et al. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism Relat Disord 2015;21:106-110.
9. Srivatsal S, Cholerton B, Leverenz JB, et al. Cognitive profile of LRRK2-related Parkinson's disease. Mov Disord 2015;30:728-733.
10. Marras C, Schule B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011;77:325-333.
11. [Erratum appears in Neurology. 2011 Oct 11;77(15):1501 (Note: Schuele, B corrected to Schule, B)].
12. Johansen KK, Waro BJ, Aasly JO. Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers. Acta Neurol Scand 2014;129:300-306.
13. Gaig C, Vilas D, Infante J, et al. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease. PLoS One 2014;9:e108982.
14. Saunders-Pullman R, Mirelman A, Wang C, et al. Olfactory Identification in LRRK2 G2019S Mutation Carriers: A relevant marker?. Ann Clin Transl Neurol 2014;1:670-678.
15. Goldwurm S, Zini M, Di Fonzo A, et al. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord 2006;12:410-419.
16. Trinh J, Amouri R, Duda JE, et al. Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. Neurobiol Aging 2014;35:1125-1131.
17. Wang C, Cai Y, Gu Z, et al. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals. NeurobiolAging 2014;35:725.e721-726.
18. Alcalay RN, Mirelman A, Saunders-Pullman R, et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 2013;28:1966-1971.
19. Lesage S, Janin S, Lohmann E, et al. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol 2007;64:425-430.
20. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005;365:410-412.
21. Brockmann K, Groger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011;26:2335-2342.
22. Alcalay RN, Aasly J, Berg D, et al. Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. Genet Med 2014;16:644-645.
23. Doty RL. The smell identification test administration manual. In: Sensonics I, ed. Haddon Heights, NJ; 1995.
24. Goetz CG, Stebbins GT, Tilley BC. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord 2012;27:1239-1242.
25. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-1534.
26. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord 2013;28:668-670.
27. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
28. Gao C, Pang H, Luo XG, Ren Y, Shang H, He ZY. LRRK2 G2385R variant carriers of female Parkinson's disease are more susceptible to motor fluctuation. J Neurol 2013;260:2884-2889.
29. [Erratum appears in J Neurol 2014;261(1):250].
30. Oosterveld LP, Allen JC Jr, Ng EY, et al. Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants. Neurology 2015;85:1039-1042.
31. Post B, Merkus MP, de Haan RJ, Speelman JD, Group CS. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007;22:1839-1851; quiz 1988.
32. Tan EK, Zhao Y, Skipper L, et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 2007;120:857-863.
33. Gan-Or Z, Leblond CS, Mallett V, Orr-Urtreger A, Dion PA, Rouleau GA. LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. Parkinsonism Relat Disord 2015;21:778-782.
34. Pont-Sunyer C, Iranzo A, Gaig C, et al. Sleep disorders in parkinsonian and nonparkinsonian LRRK2 mutation carriers. PLoS One 2015;10(7):e0132368.
35. Saunders-Pullman R, Alcalay RN, Mirelman A, et al. REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers. Mov Disord 2015;30(13):1834-1839.
36. Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12:443-453.